Roche COBAS AmpliScreen
This article was originally published in The Gray Sheet
Executive Summary
HIV and HCV nucleic acid amplification test (NAT) screening assays gain biologics license application approval for use with the AmpliScreen system for the blood bank industry. Both plasma screening tests employ the firm's polymerase chain reaction (PCR) technology and are qualitative in vitro tests. The firm announced the AmpliScreen system's 510(k) clearance in December (1"The Gray Sheet" Dec. 9, 2002, In Brief). FDA also grants 510(k) clearance for a data output management/collection system to aid in the gathering of specimen and test data...
You may also be interested in...
Roche Tests Positive With FDA Panel: Hep B Blood Screen License Endorsed
Roche Molecular System's Cobas AmpliScreen hepatitis B virus nucleic acid test for whole blood is sensitive and specific enough to be licensed as a donor screen, according to FDA's Blood Products Advisory Committee
Roche COBAS AmpliScreen
Automated nucleic acid amplification test (NAT) system gains 510(k) clearance. The laboratory PCR-based system will be used with NAT plasma screening assays for HCV and HIV-1, pending FDA approval. A BLA for the tests was filed earlier this year...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.